Tobinai, Kensei <br/><br/>
Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab.  [electronic resource] 

 -  Cancer science  Jul 2009 
 - 1344-50 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>1349-7006 
<br/><br/><label>Standard No.: </label>10.1111/j.1349-7006.2009.01162.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Cladribine--administration & dosage<br/>Dose-Response Relationship, Drug<br/>Female<br/>Humans<br/>Infusions, Intravenous<br/>Lymphoma, B-Cell--drug therapy<br/>Male<br/>Middle Aged<br/>Recurrence<br/>Rituximab